A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.
UCL spinout company, Endomagnetics Ltd, has been shortlisted for the ACES final in 2012
20 December 2011
The ACES (Academic Enterprise Awards) programme, formed to promote innovation in Europe, is holding its fourth annual awards final in Brussels next year.
Selected as one of three finalists in the Life Sciences award category, Endomagnetics Ltd is to participate in the two day "Start up! The European Entrepreneurship Summit" event.
Professor Quentin Pankhurst, Chief Technology Officer of Endomagnetics, who will be representing the company at the final, said "It's a real honour to be in the running for one of the ACES awards, and a welcome recognition of all the hard work that the whole team has put in. In 2011 we passed the CE audit for our injectable Sienna+ magnetic tracer which, coupled with our existing CE marked product, the SentiMagTM, is being prepared for a European launch in 2012. It is a very exciting time."
Endomagnetics was founded to address cancer staging and healthcare challenges through the application of advanced magnetic sensing technology. Endomagnetics is developing a portfolio of medical device products based on a patented ability to detect magnetic materials in the human body with exceptional sensitivity. The technology was originally developed at University College London and the University of Houston. The company's first product, the SentiMagTM, is an ultrasensitive hand-held probe for detecting nanoscale magnetic materials in the human body. London-based Endomagnetics is in the process of delivering its technology to global markets. For more information please visit www.endomagnetics.com.
UCLB is a leading technology transfer company that supports and commercialises research and innovations arising from UCL, one of the UK's top research-led universities.
UCLB has a successful track record and a strong reputation for identifying and protecting promising new technologies and innovations from UCL academics. It invests directly in development projects to maximise the potential of the research and manages the commercialisation process of technologies from the laboratory to market.
UCLB supports UCL's Grand Challenges of increasing UCL's positive impact on and contribution to Global Health, Sustainable Cities, Intercultural Interaction and Human Wellbeing.
For further information, please visit www.uclb.com